- Home
- ANTX vs MRSN Comparison
ANTX vs MRSN Comparison
Compare ANTX & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- MRSN
- Stock Information
- Founded
- ANTX 2017
- MRSN 2001
- Country
- ANTX United States
- MRSN United States
- Employees
- ANTX 36
- MRSN N/A
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- ANTX Health Care
- MRSN Health Care
- Exchange
- ANTX Nasdaq
- MRSN Nasdaq
- Market Cap
- ANTX 38.5M
- MRSN 36.4M
- IPO Year
- ANTX 2022
- MRSN 2017
- Fundamental
- Price
- ANTX $1.26
- MRSN $0.35
- Analyst Decision
- ANTX Buy
- MRSN Buy
- Analyst Count
- ANTX 4
- MRSN 3
- Target Price
- ANTX $3.50
- MRSN $4.00
- AVG Volume (30 Days)
- ANTX 79.8K
- MRSN 3.1M
- Earning Date
- ANTX 05-13-2025
- MRSN 05-08-2025
- Dividend Yield
- ANTX N/A
- MRSN N/A
- EPS Growth
- ANTX N/A
- MRSN N/A
- EPS
- ANTX N/A
- MRSN N/A
- Revenue
- ANTX N/A
- MRSN $40,497,000.00
- Revenue This Year
- ANTX N/A
- MRSN N/A
- Revenue Next Year
- ANTX N/A
- MRSN N/A
- P/E Ratio
- ANTX N/A
- MRSN N/A
- Revenue Growth
- ANTX N/A
- MRSN 9.88
- 52 Week Low
- ANTX $0.87
- MRSN $0.26
- 52 Week High
- ANTX $3.07
- MRSN $3.83
- Technical
- Relative Strength Index (RSI)
- ANTX 44.61
- MRSN 44.90
- Support Level
- ANTX $1.18
- MRSN $0.31
- Resistance Level
- ANTX $1.33
- MRSN $0.40
- Average True Range (ATR)
- ANTX 0.09
- MRSN 0.05
- MACD
- ANTX -0.01
- MRSN 0.01
- Stochastic Oscillator
- ANTX 42.86
- MRSN 68.09
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.